Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Authors
Keywords
Gastric cancer, Claudiximab, IMAB362, Targeted therapy, Anti-claudin antibody
Journal
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-05-12
DOI
10.1186/s13045-017-0473-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY
- (2017) T. Trarbach et al. ANNALS OF ONCOLOGY
- LBA-06IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer
- (2016) S. E. Al-Batran et al. ANNALS OF ONCOLOGY
- Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs
- (2016) Xiaofeng Wang et al. Journal of Hematology & Oncology
- A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway
- (2016) Jing Liu et al. Journal of Hematology & Oncology
- Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
- (2016) Jing Yu et al. Journal of Hematology & Oncology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started